EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer

Elizabeth Magno iD, Karen M Bussard iD

International Journal of Molecular Sciences · 17.03.2024 · 25 (6) · 3407

DOI: 10.3390/ijms25063407 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 17.03.2024. Verfasst von Elizabeth Magno und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 184 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: United States Department of Defense, Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite treatment advances, breast cancer remains a leading cause of death of women in the United States, mostly due to metastatic disease. Bone is a preferential site for breast cancer metastasis, and most metastatic breast cancer patients experience bone involvement at the time of death. The majority of patients with bone metastatic breast cancer are first diagnosed with and treated for early-stage disease, and from development of early-stage breast cancer to the recurrence of cancer in the bones, up to 30 years may elapse. Throughout this timeframe, a typical patient undergoes many treatments that have effects on the bone microenvironment. Therefore, this review explores the clinical course of a representative patient with hormone receptor-positive bone metastatic breast cancer, examining key treatment options at each stage and their effects on preventing and treating bone metastases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsBone NeoplasmsFemaleHumansUnited StatesBone and BonesBreastDisease ProgressionErb-b2 Receptor Tyrosine KinasesTumor Microenvironment

Stichwörter der Autor:innen

bisphosphonatesbonebone metastasisbone modifying agentsbreast cancerchemotherapyendocrine therapyradiation therapytumor microenvironment

Substanzen

Erb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University, Philadelphia, PA 19107, USA.

ORCID-Profile: Elizabeth Magno, Karen M Bussard

Förderung

  • United States Department of Defense
  • Department of Defense

Zitieren

APA

Magno, E., & Bussard, K. M. (2024). A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer. International Journal of Molecular Sciences, 25(6), 3407. https://doi.org/10.3390/ijms25063407

Vancouver

Magno E, Bussard KM. A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer. International Journal of Molecular Sciences. 2024;25(6):3407. doi:10.3390/ijms25063407

BibTeX
@article{Magno2024,
  author = {Magno, Elizabeth and Bussard, Karen M},
  title = {A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {6},
  pages = {3407},
  doi = {10.3390/ijms25063407}
}
Kostenlos starten →